<DOC>
	<DOC>NCT00740194</DOC>
	<brief_summary>Aromatase inhibition versus estradiol during 1 week</brief_summary>
	<brief_title>Reciprocal Influence of Sex Steroid Environment and Adipocyte Function in Men</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Informed consent obtained. Male subjects Age 18 40 weight &lt; 120 kg Primary hypogonadism or secondary hypogonadism due to genetic causes (Kallman syndrome etc.), tumors, infiltrative diseases, infections, pituitary apoplexy, trauma, critical illness, chronic systemic illness or intentional. Treatment with insulin, corticoids, opiates (on a daily basis), androgen or estrogen analogs or CYP2A6 substrates (Dexmedetomidine, Ifosfamide, Methoxsalen, Miconazole, Tranylcypromine). Impaired renal function defined as serumcreatine &gt; 1.5 mg/dL Impaired liver function, defined as ALAT &gt; 2.5 times upper limit of normal Clinically significant active cardiovascular disease including history of myocardial infarction within the past 6 months and/or heart failure (NYHA class III or IV) at the discretion of the investigator Cancer or any clinically significant disease or disorder, which in the investigator's opinion could interfere with the results of the trial Palpable prostate nodule or induration, PSA &gt; 3 ng/mL, prostatism, untreated sleep apnee syndrome, erythrocytosis (hematocrit &gt; 50%) or hyperviscosity. Known or suspected abuse of alcohol or narcotics Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Physiology</keyword>
	<keyword>males</keyword>
</DOC>